Biotechnology / Medical Research
Senomyx Inc Issues FY 2013 Guidance In Line With Analysts' Estimates
Senomyx Inc announced that for fiscal 2013, it continues to expect total revenues of $31 million to $34 million, net loss of $8 million to $10 million and basic and diluted net loss of $0.20 to $0.25 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to...
Ligand Pharmaceuticals Inc Reaffirms FY 2013 Guidance; Issues Q3 2013 Guidance; EPS Guidance Below Analysts' Estimates
Ligand Pharmaceuticals Inc announced that it is affirming its previous fiscal 2013 financial forecast, the Company expects total revenues to be between $43.0 million and $46.0 million, and non-GAAP earnings per diluted share to be between $0.47 and $0.51. For the third quarter of 2013, Ligand...
Astex Pharmaceuticals Inc Raises FY 2013 Revenue Guidance; Lowers FY 2013 Net Income Guidance
Astex Pharmaceuticals Inc announced that for fiscal 2013, revised from $55 million to $63 million, net loss has been reduced from the previous guidance of $30 million to a revised $25 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $59 million and...
ViroPharma Inc Reaffirms FY 2013 Worldwide Net Product Sales Guidance
ViroPharma Inc announced that for fiscal 2013, it expects worldwide net product sales to be $440 million to $465 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $449 million for fiscal 2013.
Mergers & Acquisitions
- Pharmathene Inc Announces Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
- Actelion Ltd Actelion US Holdings Co Enters Into Agreement To Acquire Ceptaris Therapeutics
- Novavax Inc Extends Acceptance Period for Shares in Isconova AB; Plans to Apply for Delisting of Isconova-Direkt
Restructuring & Reorganization
Expansion & New Markets
Markets
- Sectors
- U.S.
- Europe
- Asia
Sector Summary
| Energy | |
| Basic Materials | |
| Industrials | |
| Cyclical Goods & Services | |
| Non-Cyclical Goods & Services | |
| Financials | |
| Healthcare | |
| Technology | |
| Telecoms | |
| Utilities |
| DOW | 15,613.16 | +0.73% | |
| S&P 500 | 1,703.24 | +1.04% | |
| NASDAQ | 3,663.92 | +1.04% | |
| TR US Index | 155.06 | +1.13% |
Upcoming Events
No related earnings announcements are currently scheduled within the next 7 days.
Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

